ArticleCancer biomarkers : section A of Disease markers2018
CD9 expression indicates a poor outcome in acute lymphoblastic leukemia.
Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Dynamic expression of CD9 protein in T-cell acute lymphoblastic leukemia.Cancer gene therapy · 2026Article
- Review
- CD9 antibody enhances the anti-leukemia efficacy of γδT cells in adult B cell acute lymphoblastic leukemia.iScience · 2025Article
- CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts.American journal of clinical pathology · 2025Article
- Tissue Biomarkers Predicting Lymph Node Status in Cutaneous Melanoma.International journal of molecular sciences · 2022Review
- Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma.International journal of molecular sciences · 2022Article
- Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis.Cancer cell international · 2021Review
- LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL.Biomarker research · 2021Article
- Article
- CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.Molecular medicine reports · 2020Article
- Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation.Immuno-oncology technology · 2020Review
- Article
- Opportunities for Antibody Discovery Using Human Pluripotent Stem Cells: Conservation of Oncofetal Targets.International journal of molecular sciences · 2019Review
- CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.Cancer medicine · 2019Article
- Rac GTPases in Hematological Malignancies.International journal of molecular sciences · 2018Review
- Expression and Function of Tetraspanins and Their Interacting Partners in B Cells.Frontiers in immunology · 2018Review
- CD9 Tetraspanin: A New Pathway for the Regulation of Inflammation?Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe undertook a single-center retrospective study to determine the relationship between CD9 and acute lymphoblastic leukemia (ALL). MATERIALS AND
methodsIn total, 112 newly diagnosed patients in our center were enrolled in the study. Their clinical information was collected and the patients werefollowed over the course of the study. Flow cytometry was used to detect the expression of CD9.
resultsCD9 expression was more common in B cell acute lymphoblastic leukemia (B-ALL) and patients > 40 years old. CD9-positive patients exhibited a higher BCR-ABL fusion gene positive rate and higher neutrophil counts than CD9 negative patients (P= 0.004 and P= 0.004, respectively). Response to induction chemotherapy was not dependent on CD9 expression. CD9-positive patients had a lower 2-year overall survival rate than CD9-negative patients.
conclusionCD9 expression predicts some clinical characteristics and indicates an unfavorable prognosis in ALL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.